CD86 and neoplasm: This might be due to the upregulated PD‐1/PD‐L1 expression by QTPlus‐AM21 as demonstrated in vitro and in vivo which enhanced the immune escape of tumors(Figures 5A,B and 10B,C).[61] Nonetheless, QTPlus‐AM21 treatment to syngeneic tumor‐bearing mice successfully increased CD45+ tumor‐infiltrated immune cells and F4/80+ CD86+ M1 populations in TME (Figure 9), suggesting that QTPlus‐AM21 could turn tumor “hot” with more tumor‐infiltrated immune cells which would be beneficial for additional immunotherapies.[62]